Audeo Oncology (Audeo Oncology) 12-1 Month Momentum % : N/A% (As of May. 14, 2024)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-14), Audeo Oncology's 12-1 Month Momentum % is N/A%.

The industry rank for Audeo Oncology's 12-1 Month Momentum % or its related term are showing as below:

AURX's 12-1 Month Momentum % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: -6.43
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Competitive Comparison of Audeo Oncology's 12-1 Month Momentum %

For the Drug Manufacturers - General subindustry, Audeo Oncology's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Audeo Oncology's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Audeo Oncology's 12-1 Month Momentum % falls into.

Audeo Oncology (DELISTED:AURX) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Audeo Oncology (DELISTED:AURX) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Audeo Oncology 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » 12-1 Month Momentum %

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.